MX357656B - Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias. - Google Patents

Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.

Info

Publication number
MX357656B
MX357656B MX2015002604A MX2015002604A MX357656B MX 357656 B MX357656 B MX 357656B MX 2015002604 A MX2015002604 A MX 2015002604A MX 2015002604 A MX2015002604 A MX 2015002604A MX 357656 B MX357656 B MX 357656B
Authority
MX
Mexico
Prior art keywords
microglobulin
mitochondria
alpha
treatment
related diseases
Prior art date
Application number
MX2015002604A
Other languages
English (en)
Other versions
MX2015002604A (es
Inventor
Akerström Bo
Gram Magnus
Rosenlöf Lena
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of MX2015002604A publication Critical patent/MX2015002604A/es
Publication of MX357656B publication Critical patent/MX357656B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a alfa-1-microglobulina para usarse en el tratamiento de una enfermedad relacionada a mitocondrias.
MX2015002604A 2012-09-05 2013-09-04 Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias. MX357656B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270538 2012-09-05
DKPA201270557 2012-09-12
PCT/EP2013/068270 WO2014037390A1 (en) 2012-09-05 2013-09-04 Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Publications (2)

Publication Number Publication Date
MX2015002604A MX2015002604A (es) 2015-06-10
MX357656B true MX357656B (es) 2018-07-18

Family

ID=49162118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002604A MX357656B (es) 2012-09-05 2013-09-04 Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.

Country Status (22)

Country Link
US (1) US10226507B2 (es)
EP (1) EP2900254B1 (es)
JP (2) JP2015533790A (es)
KR (1) KR20150047510A (es)
CN (1) CN104661673A (es)
AU (1) AU2013311714C1 (es)
BR (1) BR112015003957A2 (es)
CA (1) CA2881321A1 (es)
DK (1) DK2900254T3 (es)
EA (1) EA028963B1 (es)
ES (1) ES2599034T3 (es)
HK (1) HK1210585A1 (es)
HR (1) HRP20161364T1 (es)
HU (1) HUE030559T2 (es)
IN (1) IN2015DN00515A (es)
MX (1) MX357656B (es)
NZ (1) NZ629621A (es)
PL (1) PL2900254T3 (es)
PT (1) PT2900254T (es)
SG (1) SG11201500669SA (es)
WO (1) WO2014037390A1 (es)
ZA (1) ZA201500547B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016204360A (ja) * 2015-02-25 2016-12-08 エー１エム ファーマ エービーＡ１Ｍ Ｐｈａｒｍａ ＡＢ 放射性核種療法における腎臓の保護に用いるためのアルファ−１−ミクログロブリン
US20190054142A1 (en) * 2016-02-25 2019-02-21 A1M Pharma Ab Alpha-1-microglobulin for use in the protection of kidneys in connection with use of contrast media
AU2017235608B2 (en) * 2016-03-18 2020-10-22 Guard Therapeutics International AB Novel alpha-1-microglobulin derived proteins and their use
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法
CN110452980B (zh) * 2019-09-23 2023-07-28 武汉儿童医院 一种线粒体脑肌病诊断试剂盒及应用
US20220362293A1 (en) * 2019-09-25 2022-11-17 Cytegen Corp. Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products
CN115575646B (zh) * 2022-11-21 2023-04-28 四川大学华西医院 一种代谢标志物组在制备预测癫痫发作的试剂盒中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547124A1 (en) * 2003-11-26 2005-06-09 Sanofi-Aventis Deutschland Gmbh Tubular proteinuria as an indicator for elevated cardiovascular risk
MX347788B (es) * 2007-02-12 2017-05-12 A1M Pharma Ab Diagnosis y tratamiento de preeclampsia.
SI2300614T1 (sl) * 2008-02-04 2016-02-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Metode in sestavki za zdravljenje mitohondrijskih motenj
ES2614490T3 (es) 2008-07-18 2017-05-31 A1M Pharma Ab Uso médico de la alfa 1-microglobulina antioxidante y eliminadora de radicales

Also Published As

Publication number Publication date
ES2599034T3 (es) 2017-01-31
CN104661673A (zh) 2015-05-27
AU2013311714B2 (en) 2017-10-12
JP2015533790A (ja) 2015-11-26
HK1210585A1 (en) 2016-04-29
BR112015003957A2 (pt) 2017-08-08
IN2015DN00515A (es) 2015-06-26
EP2900254B1 (en) 2016-08-03
ZA201500547B (en) 2017-09-27
HRP20161364T1 (hr) 2016-12-16
EA028963B1 (ru) 2018-01-31
SG11201500669SA (en) 2015-02-27
PT2900254T (pt) 2016-10-18
CA2881321A1 (en) 2014-03-13
AU2013311714C1 (en) 2018-01-25
PL2900254T3 (pl) 2017-02-28
EA201590503A1 (ru) 2015-06-30
US10226507B2 (en) 2019-03-12
WO2014037390A1 (en) 2014-03-13
AU2013311714A1 (en) 2015-03-12
NZ629621A (en) 2015-09-25
JP2018203756A (ja) 2018-12-27
MX2015002604A (es) 2015-06-10
KR20150047510A (ko) 2015-05-04
HUE030559T2 (en) 2017-05-29
US20150258171A1 (en) 2015-09-17
EP2900254A1 (en) 2015-08-05
DK2900254T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
HK1222552A1 (zh) 索布替羅用於治療髓鞘形成疾病
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
MX357656B (es) Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
HK1201438A1 (en) Treatment of ocular disease
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
EP2882429A4 (en) METHOD FOR TREATING NEURODEEGENERATIVE ILLNESSES
HK1204452A1 (en) Treatment for bone diseases
HK1211213A1 (en) Treatment of diseases involving mucin
GB2518801B (en) Improvements in, or relating to, caskets or coffins
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IN2014KN01772A (es)
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
GB201204645D0 (en) Treatment of disease
AU2012905519A0 (en) Treatment of diseases involving mucin
GB201100455D0 (en) Methods relating to treatment

Legal Events

Date Code Title Description
FG Grant or registration